In the joint program “JOINUS”, the 3 companies will commission work to universities and ventures to reevaluate compound libraries that have already shown pharmacological activity and basic safety in non-clinical studies. More than 50 kinds of mechanisms of action are targeted, and the number of concrete compounds is not disclosed.
Astellas news release, October 11, 2017
Astellas Pharma, Daiichi Sankyo and Mitsubishi Tanabe Pharma to re-evaluate compound libraries through universities and ventures